Читать книгу Blood and Marrow Transplantation Long Term Management - Группа авторов - Страница 15

Since the first three cases of successful allo‐HCT in 1968, the number of HCTs performed annually has increased steadily over the past several decades and continues to do so each year [1–3]. Advances in HCT practice and supportive care have led to improved outcomes and an increasing number of long‐term HCT survivors.

Historically, the limitation of allo‐HCT has been transplant‐related mortality (TRM) and the availability of a compatible donor. In order to offer the curative allo‐HCT treatment option in most patients, safer regimens with acceptable GVHD‐associated morbidity and TRM are preferred, and donor availability have been expanded. In this era, a stem cell source can be found for virtually all patients who have an indication to receive allo‐SCT. All of these advances result in steadily increasing numbers of long‐term survivors after HCT, creating an expanding pool of children, and young and mature adults who are at risk of long‐term complications of HCT [18].

Figure 1.1 Timelines for post‐HCT late effects.

(Source: Courtesy of Prof. John Barrett.)